Logo image
Back
Erythropoietin in Stroke Therapy: Friend or Foe
Journal article   Peer reviewed

Erythropoietin in Stroke Therapy: Friend or Foe

Rhonda Souvenir, Desislava Doycheva, John H Zhang and Jiping Tang
Current medicinal chemistry, Vol.22(10), pp.1205-1213
01/01/2015
DOI: 10.2174/0929867322666150114152134
PMCID: PMC4497368
PMID: 25620101

View Online

Abstract

Recombinant human erythropoietin (rhEPO), over the past decade, was hailed as an auspicious therapeutic strategy for various types of brain injuries. The promising results from experiments conducted in animal models of stroke led to a hurried clinical trial that was swiftly aborted in Phase II. The multiple neuroprotective modalities of rhEPO failed to translate smoothly to human adult ischemic brain injury and provided limited aid to neonates. In light of the antithetical results, several questions were raised as to why and how this clinical trial failed. There was bolstering evidence from the preliminary studies that pointed to a bright future. Therefore, the objective of this review is to address these questions by discussing the signaling pathways of rhEPO that are reported to mediate the neuroprotective effect in various animal models of brain injury. Major biomedical bibliographical databases (MEDLINE, ISI, PubMed, and Cochrane Library) were searched with the use of keywords such as erythropoietin, stroke, neonatal hypoxia ischemia, intracerebral hemorrhage, etc. This article will discuss the confounding factors that influence the efficacy of rhEPO treatment hence challenging its clinical translatability. Lastly, rhEPO may still be a promising therapeutic candidate for neonates in spite of its shortcoming in clinical trial if caution is taken with the dose and duration of its administration.
 Erythropoietin signaling janus kinase 2 signal transducers and activators of transcription 3

Details

Metrics

6 Record Views
23 Times Cited - Web of Science
Logo image